Corcept Therapeutics vs Rhythm Pharmaceuticals
Corcept Therapeutics (CORT), health care, and Rhythm Pharmaceuticals (RYTM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Rhythm Pharmaceuticals is worth $8.1B on the stock market and Corcept Therapeutics $7.7B: Rhythm Pharmaceuticals is valued at 5% more. Corcept Therapeutics's operating margin in its latest fiscal year was 5.88% and Rhythm Pharmaceuticals's -101%. Over the past year Corcept Therapeutics's share price has moved -7.84% and Rhythm Pharmaceuticals's +6.93%.
Key facts
- Corcept Therapeutics market value
- $7.7B
- Rhythm Pharmaceuticals market value
- $8.1B
- Corcept Therapeutics P/E
- 52.7
- Corcept Therapeutics revenue
- $761.4MFY to 2025-12-31
- Rhythm Pharmaceuticals revenue
- $189.8MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Corcept Therapeutics | Rhythm Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.7Blower | $8.1Bhigher |
| Revenue | $761.4Mhigher | $189.8Mlower |
| Earnings | $99.7Mhigher | -$196.5Mlower |
| Employees | 730higher | 414lower |
| Total assets | $836.7Mhigher | $480.2Mlower |
| Valuation | ||
| P/E | 52.7 | — |
| P/S | 10.1lower | 42.6higher |
| P/B | 9.2lower | 91.9higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 5.88%higher | -101%lower |
| Balance sheet | ||
| Net assets | $647.8Mhigher | $139.1Mlower |
| Total liabilities | $188.8Mlower | $210.2Mhigher |
| Total debt | — | $108.2M |
| Cash on hand | $120.5Mhigher | $54.3Mlower |
| Price change | ||
| Today | +1.23%lower | +8.49%higher |
| 1 year | -7.84%lower | +6.93%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Corcept Therapeutics only (1)
Rhythm Pharmaceuticals only (4)
Percentages are each holding's share of that investor's reported portfolio. Who owns CORT · Who owns RYTM
More on Corcept Therapeutics
Further comparisons
Corcept Therapeutics against its closest peers
Rhythm Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, Corcept Therapeutics or Rhythm Pharmaceuticals?
By market value, Rhythm Pharmaceuticals is the larger: $8.1B against $7.7B for Corcept Therapeutics. By revenue in its latest fiscal year, Corcept Therapeutics is the larger: $761.4M against $189.8M for Rhythm Pharmaceuticals.
Which has the higher operating margin?
Corcept Therapeutics: 5.88%, against -101% for Rhythm Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Corcept Therapeutics and Rhythm Pharmaceuticals?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Corcept Therapeutics and 4 hold Rhythm Pharmaceuticals.
Cite this page
Funkfolio, “Corcept Therapeutics vs Rhythm Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/cort-vs-rytm
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.